Croatia - Tiếng Croatia - HALMED (Agencija za lijekove i medicinske proizvode)

neuraxpharm arzneimittel gmbh, elisabeth-selbert-straße 23, langenfeld, njemačka - levomepromazinmaleat - filmom obložena tableta - 100 mg - urbroj: jedna tableta sadrži 100,0 mg levomepromazina (u obliku levomepromazinmaleata).

Croatia - Tiếng Croatia - HALMED (Agencija za lijekove i medicinske proizvode)

neuraxpharm arzneimittel gmbh, elisabeth-selbert-straße 23, langenfeld, njemačka - levomepromazinmaleat - filmom obložena tableta - 25 mg - urbroj: jedna tableta sadrži 25,0 mg levomepromazina (u obliku levomepromazinmaleata)

Croatia - Tiếng Croatia - HALMED (Agencija za lijekove i medicinske proizvode)

bomi-lab d.o.o., zagreb - in vitro dijagnostika, probirni testovi na 20 i 88 nutritivne alergene

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - svinjski circovirus tip 2 orf2 proteina - imunološke za suidae - svinje - za aktivne imunizacije svinja u dobi od dva tjedna od svinjske цирковирус tipa 2 (pcv2) smanjiti smrtnost, kliničke znakove, uključujući gubitak težine i poraza u лимфоидных tkivima, u svezi s ЦВС2-bolest povezana s (pcvd). osim toga, cijepljenje je pokazalo da smanjuje pcv2 nazalno prolijevanja, virusni opterećenje u krvi i limfna tkiva, te trajanje viremije. početak zaštite dolazi već dva tjedna nakon cijepljenja i traje najmanje 17 tjedana.

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp1338 virus - Иммуностимуляторы, antitumorski i иммуномодулирующие agenti, иммуностимуляторы, - mačke - imunoterapija koristi se u kombinaciji sa operacije i radioterapije kod mačaka s фибросаркомой (2-5 cm u promjeru) bez metastaza i lumps intervencija, smanjiti rizik od recidiva i povećati vrijeme do recidiva (lokalnog recidiva ili metastaza).

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.